Search
Searching Content indexed under Food and Drugs Law by Orrick ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Up In Smoke: New York City Bans Pre-Employment Drug Testing For Marijuana
Effective May 10, 2020, New York City employers may no longer test prospective employees for marijuana and tetrahydrocannabinols (THC)
United States
19 Jun 2019
2
Dusting The Regulatory Framework – French Competition Authority Seeks To Liberalize Distribution Of Drugs And Private Medical Biology
On April 4, 2019, just three months after the publication of the European Commission (EC) report on "Competition enforcement in the pharmaceutical sector,"
United States
15 May 2019
3
"I'm Not Throwing Away My [P]ot": Delaware Court Upholds Medical Marijuana User's Claims Against Employer
In Chance v. Kraft Heinz Foods Company, a Delaware state court recently held that a private cause of action exists under the state's Medical Marijuana Act (DMMA) and confirmed that the federal Controlled Substances Act (CSA) does not preempt the DMMA.
United States
22 Jan 2019
4
Connecticut Employer's Defenses On Medical Marijuana User's Discrimination Claim Go Up In Smoke
A federal court in Connecticut recently granted summary judgment to a prospective employee on an employment discrimination claim brought under Connecticut's Palliative Use of Marijuana Act (PUMA)
United States
25 Sep 2018
5
Connecticut Employer's Defenses On Medical Marijuana User's Discrimination Claim Go Up In Smoke
A federal court in Connecticut recently granted summary judgment to a prospective employee on an employment discrimination claim brought ...
United States
19 Sep 2018
6
Ninth Circuit Smells A Rat And Reinstates Claim That Pharmaceutical Company Failed To Disclose Cancers In Animal Testing
The Ninth Circuit recently revived a securities class action against Arena Pharmaceuticals issuing a decision with important guidance to pharmaceutical companies...
United States
17 Nov 2016
7
Rick Goldstein Weighs In On Reversal Of Price-Fixing Verdict Against Chinese Vitamin C Manufacturers
Rick Goldstein, an Antitrust & Competition partner in Orrick's New York office, recently spoke with Policy and Regulatory Report regarding the U.S. Court of Appeals...
United States
30 Sep 2016
8
Second Circuit Squeezes The Juice Out Of Vitamin C Jury Verdict
The U.S. Court of Appeals for the Second Circuit issued an opinion in In re Vitamin C Antitrust Litigation, reversing the district court's eight year-old decision not to grant a motion...
United States
26 Sep 2016
9
Supreme Court's Request For Views Of The United States On Cert. Petition In Lamictal "Reverse-Payment" Case Flags Potential Issues For Practitioners
King Drug involved the settlement of patent infringement litigation over a brand-name drug used to treat epilepsy and bipolar disorder, Lamictal®, brought by GSK against Teva Pharmaceuticals under the framework of the Hatch-Waxman Act.
United States
15 Jun 2016
10
Quo Vadis FTC: What Does The Commission's Complaint Against Endo Pharmaceuticals And Others Say About The Future Of Post-Actavis Hatch-Waxman Litigation And Reverse Payment Settlements?
This alert, the title of which is adapted from a March 30, 2016 FTC Staff Attorney blog post, considers the FTC's first lawsuit challenging a so-called "no-AG" agreement.
United States
20 Apr 2016
11
Cephalon And Teva's $1.2 Billion Consent Order With The FTC: Is It Really A Harbinger Of Things To Come?
The FTC filed a complaint against Cephalon in U.S. District Court for the District of Columbia on February 12, 2008.
United States
24 Jun 2015
12
"Product Hopping": New Second Circuit Decision Addresses Antitrust Limits on Innovation and Related Marketing Activity
In late May, the U.S. Court of Appeals for the Second Circuit issued the first appellate decision addressing the pharmaceutical industry practice called by some "product hopping"...
United States
24 Jun 2015
13
Cephalon And Teva's $1.2 Billion Consent Order With The FTC: Is It Really A Harbinger Of Things To Come?
The FTC filed a complaint against Cephalon in U.S. District Court for the District of Columbia on February 12, 2008.
United States
23 Jun 2015
14
March 2015 Recap
March 2015—like January and February—saw decisions on a variety of fronts from ND Cal judges.
United States
20 Apr 2015
15
1st Circuit Clarifies Class Composition Rules For Reverse Payment Pharmaceutical Actions
On Jan. 21, 2015, a split 1st U.S. Circuit Court of Appeals panel upheld a district court order certifying a class of payors, union health and welfare funds, and individual consumers...
United States
23 Feb 2015
16
Sandoz Was Disinvited To The Patent Dance: The Federal Circuit’s First Interpretation Of The BPCIA Will Have To Wait
Since the 1984 enactment of the Drug Price Competition and Patent Term Restoration Act, Hatch-Waxman litigation has dominated the sphere of life-sciences patent litigation.
United States
6 Jan 2015
17
United States
30 Dec 2014
18
Supreme Court Rules That Food And Beverage Mislabeling Claims Do Not Foreclose Competitor's Unfair Competition Claims Under §43(a) Of The Lanham Act
On Thursday, June 12, 2014, Justice Anthony Kennedy delivered an opinion for a unanimous United States Supreme Court in POM Wonderful LLC v. The Coca-Cola Co.
United States
30 Jun 2014
19
Commission Fines Johnson & Johnson And Novartis €16 Million For Reverse Payment Regarding Generic Painkiller
On Dec. 10, 2013, the European Commission announced fines of €10.8 million imposed on Johnson & Johnson and €5.5 million on Novartis for colluding to postpone the entry of a generic version of fentanyl into the Dutch market.
United States
12 Feb 2014
Links to Result pages
 
1